916210-27-0 Usage
Uses
Used in Pharmaceutical Industry:
Tert-Butyl N-[(2-chloropyridin-4-yl)methyl]carbamate is used as an intermediate in the synthesis of pharmaceuticals for its ability to inhibit cholinesterase enzymes. This property makes it a valuable component in the development of drugs that target these enzymes, which are involved in various physiological processes and diseases.
Used in Agrochemical Industry:
In the agrochemical industry, Tert-Butyl N-[(2-chloropyridin-4-yl)methyl]carbamate is utilized as an intermediate in the production of various pesticides. Its broad spectrum of biological activity and cholinesterase inhibitory properties contribute to the effectiveness of these pesticides in controlling pests and protecting crops.
Used in Research and Development:
Tert-Butyl N-[(2-chloropyridin-4-yl)methyl]carbamate is also used in research and development for the exploration of its potential applications in various fields. Its unique chemical structure and properties make it an interesting subject for scientific studies, which may lead to the discovery of new uses and applications in the future.
Check Digit Verification of cas no
The CAS Registry Mumber 916210-27-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,1,6,2,1 and 0 respectively; the second part has 2 digits, 2 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 916210-27:
(8*9)+(7*1)+(6*6)+(5*2)+(4*1)+(3*0)+(2*2)+(1*7)=140
140 % 10 = 0
So 916210-27-0 is a valid CAS Registry Number.
916210-27-0Relevant academic research and scientific papers
COMPOUNDS USEFUL AS INHIBITORS OF HELIOS PROTEIN
-
Paragraph 0264; 0265, (2021/05/21)
Disclosed are compounds of Formula (I): or a salt thereof, wherein: Z is CR6R6 or C═O; Ring A is: and R1, R2, R3, R4, R5, m, and n are defined herein. Also disclosed are methods of using such compounds to inhibit Helios protein, and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.
CYCLOPROPANE DERIVATIVE AND DRUG CONTAINING SAME
-
Paragraph 0132, (2018/06/15)
A compound represented by the formula (I): wherein each symbol is as defined in the DESCRIPTION, or a pharmaceutically acceptable salt thereof has superior TRPA1 antagonist activity, and the compound or a pharmaceutically acceptable salt thereof is useful for the prophylaxis or treatment of diseases involving TRPA1 antagonist and TRPA1.
HETEROCYCLIC SULFONAMIDE DERIVATIVE AND MEDICINE COMPRISING SAME
-
Paragraph 0494; 0495, (2016/12/01)
The present invention provides a compound represented by the formula (I): wherein each symbol is as defined in the DESCRIPTION, or a pharmaceutically acceptable salt thereof. The compound has a superior TRPA1 antagonist activity, and can provide a medicament useful for the prophylaxis or treatment of diseases involving TRPA1 antagonist and TRPA1.
